As released on the BusinessWire, “Concentric Analgesics, Inc., a clinical-stage biopharmaceutical pain company, announced today that it has initiated a Phase 2 clinical study of CA-008, the Company’s lead product candidate for the treatment of post-surgical pain. CA-008 is a water-soluble non-opioid prodrug that rapidly converts to capsaicin, a potent TRPV1-agonist which selectively desensitizes pain conducting nerve fibers to provide long-lasting analgesia.”
TrialSite News staff review of Concentric Analgesics (CA). Founded in 2014, Concentric Analgesics is a privately held biotechnology company focused on the discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain. According to LinkedIn we estimate the company has under 20 employees. It was founded by Craig Husfeld, who has worked in San Francisco Bay Area Biotech ventures for the past 15 years. He earned his PhD in Synthetic Organic Chemistry from Stanford University. CEO is John Donavan, MD who also maintains an assistant clinical professor position at University of California, San Francisco. Donavan earned his MD from Georgetown in 1992 and has been a practicing anesthesiologist for many years. We considered their Phase I study for CA-008 at ClinicalTrials.gov
Apparently the CRO that conducted the study on behalf of CA during the Phase I trial was Lotus Clinical Research LLC, a California CRO focusing on pain research. http://www.lotuscr.com/
The Phase I study focused on post-surgical pain from bunion surgeries or known in medical community as Hallux Valgus.
Although there is no investment of any material investment CA founder and management group maintain solid credentials. According to their news releases, their “lead investigational product candidates are proprietary water-soluble prodrugs that convert into capsaicin – the naturally occurring molecule that gives chili peppers their heat and is a potent TRPV-1 agonist. Capsaicin, which has a long history of use as a topical analgesic, selectively and reversibly desensitizes pain conducting nerve fibers (C-fiber nociceptors). TRPV-1 agonism evokes an initial neuronal excitation that is followed by a durable refractory state to provide long lasting analgesia.”
View article hereSource: Business Wire